Literature DB >> 29424902

Regulatory role of CDX2 and NOX4 expression associated with recurrent nasopharyngeal carcinoma.

G Chen1, H Hao, J-W Ai.   

Abstract

OBJECTIVE: Nasopharyngeal carcinoma (NPC) is a malignancy caused by Epstein-Barr virus (EBV). NPC is radiosensitive and has a high frequency of treatment failure due to metastasis, which results in recurrent nasopharyngeal carcinoma (rNPC). PATIENTS AND METHODS: In the present study, nasopharyngeal carcinoma biopsies were obtained from NPC and rNPC patients, as well as healthy controls, and reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry, and immunoblotting analyses were performed.
RESULTS: The RTPCR data showed expression of CDX2 and NOX4 in rNPC biopsy samples but not in control or NPC samples. Immunohistochemical and immunoblotting analyses confirmed the expression of CDX2 and NOX4 in rNPC samples, but not in NPC biopsy samples.
CONCLUSIONS: The finding concludes that an association of CDX2 and NOX4 expression with rNPC was noted; thus, these proteins may have value as prognostic indicators and may facilitate the development of novel therapeutics for rNPC patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29424902     DOI: 10.26355/eurrev_201801_14194

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  MicroRNA-424-5p inhibits the proliferation, migration, and invasion of nasopharyngeal carcinoma cells by decreasing AKT3 expression.

Authors:  Chong Zhao; Feng Zhao; Huiying Chen; Yuehua Liu; Jiping Su
Journal:  Braz J Med Biol Res       Date:  2020-06-03       Impact factor: 2.590

2.  Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing.

Authors:  Wen-Sa Peng; Xin Zhou; Wen-Bin Yan; Yu-Jiao Li; Cheng-Run Du; Xiao-Shen Wang; Chun-Ying Shen; Qi-Feng Wang; Hong-Mei Ying; Xue-Guan Lu; Ting-Ting Xu; Chao-Su Hu
Journal:  Oncoimmunology       Date:  2022-01-25       Impact factor: 8.110

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.